Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 473-479

  Choi, Yung Hyun ^a,b  

^a Dong Eui University   (South Korea)

^b Dong Eui University   (South Korea)

Author keywords

Apoptosis; Bcl 2; COX 2; HDAC inhibitor; Trichostatin A

Indexed keywords

CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 3; CASPASE 9; DNA FRAGMENT; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E2; PROTEIN BCL 2; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASE 9; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DINOPROSTONE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33644688961     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.473     Document Type: Article

References (38)

1. Anderson WF. Umar A. Viner JL and Hawk ET: The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Dcs 8: 1035-1062. 2002.
2. Soh JW and Weinstein IB: Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res 37: 261-285, 2003.
3. Smith WL. Dc Witt DL and Garavito RM: Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 69: 145-182. 2000.
4. Tao X. Schulzc-Koops H. Mu L. Cai J. Mao Y and Lipsky PE: Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis Rheum 41: 130-138. 1998.
5. Repovic P. Mi K and Benveniste EN: Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-Iβ, tumor necrosis factor-α. and bacterial lipopolysaccharide. Glia 42: 433-446. 2003.
6. Crofford U: COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 49: SI5-S19. 1997.
7. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286. 2002.
8. Monneret C: Histone deaectylasc inhibitors. Eur J Med Chem 40: 1-13, 2005.
9. Peterson CL and Laniel MA: Histones and histone modifications. Curr Biol 14: R546-R551. 2004.
10. Mei S. Ho AD and Mahlknecht U: Role of histone deaectylasc inhibitors in the treatment of cancer. Int J Oncol 25: 1509-1519. 2004.
11. Arts J. De Schepper S and van Emelen K: Histone dcacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10: 2343-2350. 2003.
12. Vanhaeckc T. Papeleu P. Elaut G and Rogiers V: Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 11: 1629-1643.2004.
13. Marks PA. Richon VM. Breslow R and Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483.2001.
14. Yoshida M. Furumai R. Nishiyama M. Komatsu Y, Nishino N and Horinouchi S: Histone dcacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 (Suppl. 1): S20-S26. 2001.
15. Yoshida M. Matsuyama A. Komatsu Y and Nishino N: From discovery to the coming generation of histone dcacetylase inhibitors. Curr Med Chem 10: 2351-2358. 2003.
16. Yoshida M. Kijima M. Akita M and Beppu T: Potent and specific inhibition of mammalian histone dcacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179. 1990.
17. Yamashita Y. Shimada M. Harimoto N. Rikimaru T. Shirabe K. Tanaka S and Sugimachi K: Histone dcacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatoeyte differentiation in human hepatoma cells. Int J Cancer 103: 572-576. 2003.
18. Herold C, Ganslmayer M, Ocker M. Hermann M. Geerts A. Hahn EG and Schuppan D: The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36: 233-240, 2002.
19. Kim YB, Ki SW. Yoshida M and Horinouchi S: Mechanism of cell cycle arrest caused by histone dcacetylase inhibitors in human carcinoma cells. J Antibiot 53: 1191-200, 2000.
20. Sowa Y, Orita T, Minamikawa S, Nakano K. Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor activates the WAFI/Cipl gene promoter through the Spl sites. Biochem Biophys Res Commun 241: 142-150,1997.
21. Suzuki T. Yokozaki H. Kuniyasu H. Hayashi K. Naka K, Ono S. Ishikawa T. Tahara E and Yasui W: Effect of trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 88: 992-997. 2000.
22. Bouchain G and Delorme D: Novel hydroxamate and anilide derivatives as potent histone deacetylasc inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem 10: 2359-2372. 2003.
23. Choi YH. Lee SJ. Nguyen P. Jang JS. Lee J. Wu ML. Takano E. Maki M. Henkart PA and Trepel JB: Regulation of cyclin DI by cal pain protease. J Biol Chem 272: 28479-28484. 1997.
24. Choi YH. Lee WH. Park KY and Zhang L: p53-independent induction of p21 (WAFl/CIPI). reduction of cyclin BI and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173. 2000.
25. Choi YH, Kong KR. Kim YA. Jung KO. Kil JH. Rhee SH and Park KY: Induction of Bax and activation of caspases during B-sitosterol-mediated apoptosis in human colon cancer cells. Int J Oncol 23: 1657-1661. 2003.
26. Gerschenson LE and Rotello RJ: Apoptosis: a different type of cell death. FASEB J 6: 2450-2455. 1992.
27. Saraste A: Morphologic criteria and detection of apoptosis. Herz 24: 189-195. 1999.
28. Walker PR and Sikorska M: New aspects of the mechanism of DNA fragmentation in apoptosis. Biochem Cell Biol 75: 287-299, 1997.
29. Miyashita T. Krajewski S. Krajewska M, Wang HG. Lin HK. Liebermann DA. Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805. 1994.
30. Rosse T. Olivier R. Monney L. Rager M. Conus S. Fellay I. Jansen B and Borner C: Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391: 496-499. 1998.
31. Stennicke HR and Salvesen GS: Properties of the caspases. Biochim Biophys Acta 1387: 17-31. 1998.
32. Earnshaw WC. Martins LM and Kaufmann SH: Mammalian caspases: structure, activation, substrates and functions during apoptosis. Annu Rev Biochem 68: 383-424, 1999.
33. Lazebnik YA. Kaufmann SH. Desnoyers S. Poirier GG and Earnshaw WC: Cleavage of poly(ADP-ribose)-polymerase by a proteinase with properties like ICE. Nature 371: 346-347, 1994.
34. Roy N. Deveraux QL. Takahashi R. Salvesen GS and Reed JC: The c-IAP-l and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16: 6914-6925. 1997.
35. Deveraux QL and Reed JC: IAP family proteins-suppressors of apoptosis. Genes Dev 13: 239-252. 1999.
36. Dempke W. Rie C. Grothey A and Schmoll HJ: Cyclo-oxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 127: 411-417. 2001.
37. Gately S and Kerbel R: Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37: 179-192. 2003.
38. Oshima M and Taketo MM: COX selectivity and animal models for colon cancer. Curr Pharm Des 8: 1021-1034. 2002.